Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection
Younis, Y., Elazab, T., Abd El-Fattah, E. (2020). Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection. EKB Journal Management System, 5(Issue 6 part (2)), 241-251. doi: 10.21608/bjas.2020.137169
Y.S. Younis; T.E. Elazab; E.M. Abd El-Fattah. "Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection". EKB Journal Management System, 5, Issue 6 part (2), 2020, 241-251. doi: 10.21608/bjas.2020.137169
Younis, Y., Elazab, T., Abd El-Fattah, E. (2020). 'Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection', EKB Journal Management System, 5(Issue 6 part (2)), pp. 241-251. doi: 10.21608/bjas.2020.137169
Younis, Y., Elazab, T., Abd El-Fattah, E. Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection. EKB Journal Management System, 2020; 5(Issue 6 part (2)): 241-251. doi: 10.21608/bjas.2020.137169

Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection

Benha Journal of Applied Sciences
Article 14, Volume 5, Issue 6 part (2), September 2020, Page 241-251  XML PDF (1.28 MB)
Document Type: Original Research Papers
DOI: 10.21608/bjas.2020.137169
View on SCiNiTO View on SCiNiTO
Authors
Y.S. Younis1; T.E. Elazab1; E.M. Abd El-Fattah2
1Hepatology, Gastroenterology and Infectious Diseases Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
2Qina Fever Hospital, Ministry of Health, Qina City, Egypt.
Abstract
The highest prevalence of chronic hepatitis C virus (HCV) was reported in Egypt. DAAs has been accessible, with a revealed 12 weeks continued virologic reaction (12w-SVR) above 95% after treatment for 12 weeks duration . was to assess adequacy and wellbeing of Sofosbuvir in addition to Daclatasvir with or without Ribavirin in Egyptian patients persistently contaminated with HCV . Study was done on 200 patients separated similarly to 2 enormous gatherings; bunch I under 65 years and gathering II over 65 years partitioned into 4 subgroups rely upon ribavirin.The first subgroup will take sofosbuvir 400mg and daclatasavir60mg (double treatment gathering), under 65 years of age ( bunch Ia ). The subsequent subgroup will take sofosbuvir 400mg, daclatasvir 60 mg and ribavirin 1000-1200 mg weight based (triple treatment gathering) under 65 years of age ( bunch Ib ). The third subgroup will take sofosbuvir 400 mg, daclatasvir 60 mg(dual treatment group)more than 65 years of age( bunch IIa )and the fourth subgroup will take sofosbuvir 400mg, daclatasvir 60 mg and ribavirin1000-1200 mg weight based(triple treatment gathering) ( bunch IIb ). The current examination show that the treatment was sheltered and compelling in all gatherings with by and large reaction of 96%, 94% 92% and 94% in bunch Ia, Ib, IIa, IIb respectively.
Keywords
Sofosbuvir; Daclatasvir; Ribavirin; HCV
Statistics
Article View: 85
PDF Download: 318